Vericel Corp (VCEL)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-06

Key Insights

  • Insider Jonathan Hopper, the Chief Medical Officer, exercised 3,472 stock options at $10.95 and immediately sold the same number of shares at $35, indicating he is likely taking some profits.
  • Hopper still holds 75,556 shares directly, suggesting he maintains a substantial ownership stake in the company.
  • The transaction was executed pursuant to a pre-arranged 10b5-1 trading plan, indicating it was part of a systematic portfolio management strategy rather than an opportunistic sale.
Filing tone (AI): Neutral
View Original Filing →
Insider Trading Filed: 2026-03-25

Key Insights

  • Heidi Hagen, a director of Vericel Corp, exercised 15,000 stock options at $2.76 per share and then immediately sold the underlying shares for $32.41 per share, indicating a significant profit on the transaction.
  • The sale was executed under a pre-arranged 10b5-1 trading plan, suggesting the transaction was part of a planned diversification or liquidity strategy rather than an opportunistic sale.
  • Hagen's remaining direct ownership of 31,850 shares represents a small fraction of Vericel's outstanding shares, indicating her stake is not a controlling or influential position.
Filing tone (AI): Positive
View Original Filing →
Insider Trading Filed: 2026-02-13

Key Insights

  • The reporting person, Kevin McLaughlin, exercised 7,000 stock options with an exercise price of $2.63 per share, indicating their confidence in the company's future performance.
  • Following the exercise, the reporting person sold 7,000 shares at an average price of $34.66 per share, likely to diversify their portfolio or meet personal financial needs.
  • The reporting person still holds 15,100 shares of Vericel Corp (VCEL) directly, suggesting they maintain a substantial investment in the company.
Filing tone (AI): Positive
View Original Filing →
Current Report Filed: 2026-01-13

Key Insights

  • Vericel Corporation provided preliminary financial results for fiscal year 2025, including estimated revenue, net income, gross margin, and adjusted EBITDA margin.
  • The company's financial statements for 2025 have not been finalized or audited, so the preliminary estimates are subject to change and the actual results may differ materially.
  • Vericel will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, where they will provide additional financial and business updates.
Filing tone (AI): Positive
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Vericel Corp filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.